|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0550 USD | +450.00% |
|
-.--% | -82.40% |
| Market Cap | 88.41M 76.27M 70.12M 66M 124M 8.34B 125M 831M 324M 4.09B 332M 325M 14.17B | P/E 2026 * |
-0.23x | P/E 2027 * | -0.23x |
|---|---|---|---|---|---|
| Enterprise Value | 43.22M 37.29M 34.28M 32.27M 60.63M 4.08B 61.14M 406M 158M 2B 162M 159M 6.93B | EV / Sales 2026 * |
12.6x | EV / Sales 2027 * | 29.7x |
| Free-Float |
-
| Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics
| 1 day | +450.00% | ||
| 3 months | -89.11% | ||
| 6 months | -82.40% | ||
| Current year | -82.40% |
| Current year | 0 |  | 0.54 |
| 1 year | 0 | | 0.54 |
| 3 years | 0 | | 0.7 |
| 5 years | 0 | | 2.36 |
| 10 years | 0 | | 4.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Niven
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.42M 2.95M 2.72M 2.56M 4.8M 323M 4.84M 32.19M 12.53M 159M 12.85M 12.58M 549M | 1.6M 1.38M 1.27M 1.19M 2.24M 151M 2.26M 15.04M 5.86M 74.12M 6.01M 5.88M 256M |
| Net income | -13.44M -11.6M -10.66M -10.03M -18.86M -1.27B -19.02M -126M -49.19M -623M -50.45M -49.37M -2.15B | -22.29M -19.23M -17.68M -16.64M -31.27M -2.1B -31.53M -210M -81.57M -1.03B -83.66M -81.87M -3.57B |
| Net Debt | -45.19M -38.98M -35.84M -33.74M -63.39M -4.26B -63.92M -425M -165M -2.09B -170M -166M -7.24B | -40.88M -35.27M -32.43M -30.52M -57.35M -3.86B -57.83M -384M -150M -1.89B -153M -150M -6.55B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- PRNAD Stock
Select your edition
All financial news and data tailored to specific country editions
